Targeted radionuclide therapy

The seeking molecule binds to a feature on or near selected cancer cells. The attached radionuclide then releases radiation close to those cells. Because the medicine travels through the body, it may reach cancer sites that cannot be treated from one external beam position. It is only suitable when testing shows that the relevant target is present.

Doctors may use this approach for selected cancers, including some neuroendocrine or blood-related conditions, depending on the medicine and your clinical situation. Treatment is planned around kidney function, blood counts, previous therapies and other medicines. It is different from external radiotherapy because the radiation source is carried inside the body.

Your team may arrange blood tests, scans and a target-detection test before treatment. Tell them about pregnancy, breastfeeding, kidney problems, medicines and any difficulty drinking fluids. You may receive fluids or protective medicines, and the team will explain practical steps for reducing other people's exposure for a limited time.

After treatment, follow the written instructions about hygiene, contact with children or pregnant people, travel and handling bodily fluids. Drink as advised and attend blood-test appointments. Fatigue, nausea, reduced appetite or changes in blood counts can occur; report symptoms early so support can be offered.

Call your treatment team promptly for fever, chills, persistent vomiting, unusual bruising, bleeding, severe weakness, reduced urine or swelling. Get urgent help for trouble breathing, collapse, confusion or a severe allergic reaction. The team may need to check blood counts, kidney function or hormone effects.

Ask what target the medicine recognises, how it was confirmed, what preparation is needed, how many treatment visits are expected, how exposure precautions work, and which symptoms require urgent advice. Ask how kidney function, blood counts and other treatments will be monitored.